Anti-Obesity Drug Increases Heart Risks

by Rajshri on  January 26, 2010 at 7:55 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

 Anti-Obesity Drug Increases Heart Risks
The US Food and Drug Administration (FDA) has asked the doctors to avoid prescribing anti obesity drugs containing sibutramine for patients who have a history of cardiovascular disease.

While the drug, which is marketed in Australia as Ectiva or Reductil and as Meridia in the United States, already carries a message which warns against consumption among patients with heart disease, the FDA has asked the makers to include those patients who have a history of cardiovascular disease.

The FDA conducted a study of 10,000 patients and found that cardiovascular events such as coronary artery disease or stroke occurred in 11.4 percent of the patients compared to just 10 percent among those who were taking a placebo.

The study has led the FDA to come out with a string of suggestions which includes physicians regularly monitoring blood pressure and heart rate of patients using sibutramine and discontinuing the drug if the patient did not lose at least 5 percent of baseline weight within the first three to six months of treatment.




Source: Medindia
RAS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Heart Healthy Heart Statins Mitral Valve Prolapse Aortic Valve Stenosis Pericarditis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive